The FDA on August 1, 2024, approved JEMPERLI® with Carboplatin and Paclitaxel, followed by single-agent JEMPERLI®, for adult patients with primary advanced or recurrent Endometrial cancer. JEMPERLI® is a product of GSK.
Bottom Ad
Advertisement
Subscribe
